Review of Studies on Metformin, Ethnicity, and Prostate Cancer Risk

Introduction

Researchers have conducted a comprehensive review of 26 studies to explore the potential effects of metformin and ethnicity on prostate cancer risk. This systematic review, led by Jeffrey Johnson and his team in Alberta, Canada, was published in BMC Cancer.

Study Selection and Population

The research team meticulously searched various databases and selected 26 studies for their analysis. Among these, 23 studies focused on Western populations (primarily from Europe and North America), while three studies involved participants from Asia, mainly Taiwan. The review included a total of 1,171,643 participants from Western countries and 400,664 participants from Asian backgrounds.

Findings on Prostate Cancer Risk

The analysis revealed no significant decrease in prostate cancer risk for either the Western or Asian groups. These findings suggest that metformin may not have a protective effect against prostate cancer across different ethnicities.

Diabetes and Cancer Connection

Type 2 diabetes is associated with an increased risk of developing certain cancers due to shared pathophysiological characteristics. Insulin resistance, a common issue in type 2 diabetes, leads to hyperinsulinemia, or an excess of insulin in the bloodstream. This condition is hypothesized to elevate cancer risk.

Metformin’s Role in Cancer Risk Reduction

Metformin, a widely used medication for managing type 2 diabetes, has garnered interest for its potential role in reducing cancer risk. Some studies suggest that ethnicity may influence the effectiveness of metformin in cancer management, indicating a possible reduction in prostate cancer risk among Asian participants.

Limitations of the Review

The review faced limitations, particularly the lack of individual participant data. This gap is significant as the studies were categorized based on database origin without accounting for the diverse ethnic backgrounds of participants. Additionally, definitions of metformin exposure varied among studies; some defined it based on the presence or absence in medication regimens, while others compared it with different medications or dietary practices.

Conclusion and Future Research

While the review indicates that there may be no correlation between metformin use and prostate cancer risk, the noted limitations highlight the need for further research in this area to better understand the relationship between metformin, ethnicity, and cancer risk.

Reference

Chen, C.B et al. Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis. BMC Cancer (2018) 18:65 DOI 10.1186/s12885-017-3934-9